Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec - Trial NCT06238778
Access comprehensive clinical trial information for NCT06238778 through Pure Global AI's free database. This Phase 2 trial is sponsored by Diasome Pharmaceuticlas, Inc. and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 230 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Diasome Pharmaceuticlas, Inc.
Timeline & Enrollment
Phase 2
Jan 23, 2024
Mar 01, 2026
Primary Outcome
hypoglycemia events,hypoglycemia percentage of time
Summary
The goal of this study is to see if directing insulin to the liver will improve the low blood
 sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants
 will use continuous glucose monitoring to measure the sugar levels in their blood, and work
 with the doctor to find the best doses. One group of patients will get the liver targeting
 insulin, and the other group will use insulin they normally use for treating Type 1 diabetes.
 The participant will be part of the study for up to 32 weeks.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06238778
Non-Device Trial